The field of traditional medicine, with its deep historical roots, offers a multitude of natural compounds with potential therapeutic benefits. Lately, ...
Recovery from deadly influenza infection may hinge on helping the lungs heal in addition to stopping the virus, according to ...
Despite a recent capital raise, Shelton-based antiviral drug developer NanoViricides Inc. disclosed it does not have enough cash to fund operations beyond mid-February and will need additional ...
Scientists were pleased when they learned more about how the common cold gains a foothold in the body, identifying key cellular checkpoints that are important targets of the virus.
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum ...
6don MSN
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara’s stock soaring 106% in recent morning trading, ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Ruvidar and Rutherrin show strong potential in treating bladder cancer, solid tumors, and HSV-1—including drug-resistant ...
The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...
Oct 22 (Reuters) - Cancer patients who received mRNA-based COVID vaccines within 100 days of starting treatment with widely used immunotherapies were twice as likely to be alive three years after ...
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback